Boston Therapeutics has released final trial results from its proof of concept (POC) Sydney University study that showed consumption of sugardown tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose and insulin responses to the sugary soft drink beverage. Every subject had a favourable response. Specifically, two sugardown tablets were found to reduce glucose levels (and by association fructose exposure) by up to 20 percent and the insulin response by up to 14%. Four sugardown tablets were found to reduce total glucose levels by up to 28% and insulin response by up to 18%. The study results indicate an average reduction in glycemic index (GI) an important measure of healthy nutritional management of approximately 10% following soft drink consumption with two sugardown tablets.